Background: Tigecycline, a member of a new class of antimicrobials (glycylcyclines), has been shown to have potent broad spectrum activity against most commonly encountered species responsible for hospital acquired infections. Cross-resistance to several classes of antimicrobials is often seen in nosocomial pathogens. The T.E.S.T. program determined the in vitro activity of tigecycline against strains of Enterobacteriaceae cross-resistant to one or more of the following antimicrobials: amoxicillin-clavulanic acid, piperacillin-tazobactam, levofloxacin, ceftriaxone, cefepime, ampicillin, amikacin, minocycline, ceftazidime and imipenem. The isolates were collected from 335 investigational sties in 47 countries throughout [2004][2005][2006][2007].
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Methods: A total of 26,791 clinical Enterobacteriaceae were identified to the species level at each site and confirmed by the central laboratory. Minimum Inhibitory Concentrations (MICs) were determined by the local laboratory using broth microdilution panels. Antimicrobial resistance was interpreted according to CLSI breakpoints with TIG susceptible and resistant breakpoints defined as = 8 mcg/ml, respectively.
Results: 1,387/16,289 (8.5%) E. coli and Klebsiella spp were ESBL producers. Of the Enterobacteriaceae presented, 13% were resistance to levofloxacin, 8% to minocycline, 1.1% to amikacin, 0.2% to imipenem, and 0.8% to tigecycline. Of the 10,348 Enterobacter spp. and S. marcescens collected, 593 (5.7%) presented resistance to ceftriaxone and ceftazidime but susceptible to cefepime suggestive of AmpC phenotype. Only 877 (3.3%) of the Enterobacteriaceae showed any degree of non-susceptibility against tigecycline with MICs ranging from 4 to 8 mcg/mL. Tigecycline also showed excellent inhibitory activity against members of Enterobacteriaceae that were resistant to amikacin, levofloxacin, minocycline and imipenem inhibiting 94%, 92%, 72% and 91% of isolates respectively.
Conclusions: The presented data suggest that tigecycline is little affected by this cross-resistance phenomenon and may be an effective and reliable therapeutic option against nosocomial or community pathogens regardless to the resistance patterns. 
